Neurocrine Biosciences Inc (NBIX)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | 0 | 335,100 | 317,900 |
| Total stockholders’ equity | US$ in thousands | 2,589,700 | 2,232,000 | 1,707,800 | 1,374,000 | 1,126,200 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.24 | 0.28 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $2,589,700K
= 0.00
The debt-to-equity ratio of Neurocrine Biosciences Inc has exhibited a decreasing trend over the past five years. As of December 31, 2020, the ratio stood at 0.28, indicating that the company had $0.28 of debt for every $1 of equity. By December 31, 2021, the ratio had decreased to 0.24, suggesting a slight reduction in the proportion of debt to equity. Notably, as of December 31, 2022, December 31, 2023, and December 31, 2024, the debt-to-equity ratio was at 0.00, implying that the company was either debt-free or had minimal debt relative to its equity during these periods. Overall, the decreasing trend in the debt-to-equity ratio indicates that Neurocrine Biosciences Inc has been effectively managing its debt levels and maintaining a healthy balance between debt and equity in its capital structure.
Peer comparison
Dec 31, 2024